Clinical trial NCT03327129: Identifying the Neural Basis of Capability for Suicide
Official title: Identifying the Neural Basis of Capability for Suicide
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Major Depressive Disorder
Suicide
Suicidal Ideation
Psychiatric Illness
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2017-10-31
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects will recruited from Mental Health Clinics at St. Michael's Hospital from Mood Disorders Clinics and self-referrals from advertisements in Mental Health Department.

Brief summary: Since capability for suicide involves overriding potential pain, and the opioid system plays a strong role in controlling pain perception, it follows that capability for suicide may be impacted by the opioid system. The goal of the proposed research is to identify the neural network underlying capability for suicide in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Detailed description: Little evidence exists distinguishing individuals with suicidal ideation (SI) from those at risk for suicidal behaviour, illustrating the need for more comprehensive biomarkers for clinicians to guide their treatment approach and for new treatment avenues. Current theories of suicide have suggested the importance of an individual's capability for suicide in predicting suicide attempt or death. Building on this, Yovell and colleagues (2016) provided important preliminary data that the opioid system affects suicide risk, but the neural mechanisms and their relationship to capability for suicide are unclear. The goal of the proposed research is to identify the neural network underlying capability for suicide using functional magnetic resonance imaging (fMRI) in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Eligibility criteria: Inclusion criteria for patients:

* Age between 18-70
* Capability of giving informed consent
* Not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels)

Exclusion criteria for patients:

* Lifetime history of any substance abuse, psychosis
* Current use of any opioid acting drugs
* Current use of any prescription pain medication
* Use of over the counter pain medications within 15 hours of brain scan
* For daily users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 12 hours of brain scan
* For as needed users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 2 weeks of brain scan. This is because non-daily use will have more unpredictable effects on brain imaging results than those who are using these medications on a regular basis. The 2 weeks will ensure the drug is not in the system.
* Medical condition requiring immediate investigation or treatment
* Participation in experimental treatment trials for the study duration.

Healthy control inclusion criteria: Ages between 18 and 70 years, capable of giving informed consent, not pregnant or lactating, no lifetime history of Axis I/II disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.

Primary outcomes:
measure: Neural network underlying acquired capability for suicide
timeFrame: 2 weeks
Secondary outcomes:
measure: Correlation between pain task performance and acquired capability for suicide
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Sakina Rizvi, PhD
role: PRINCIPAL_INVESTIGATOR
References: